Global Impact

{{tooltip.Heading}}
{{tooltip.Content}}
Mylan landing footer

Mylan has a strong and distinct focus on fighting infectious disease.

We believe everyone deserves equal access to quality medication, especially when it comes to battling HIV/AIDS. We’ve invested more than $250 million to expand antiretroviral (ARV) production capacity, and we now manufacture more than 4 billion ARV tablets each year. The result: More than 8 million people, about 40% of all patients on HIV treatment worldwide, depend on a Mylan ARV every day.

Learn More

Learn More